Creatine supplementation in Huntington’s disease

  title={Creatine supplementation in Huntington’s disease},
  author={Patricia Verbessem and Jurgen Lemiere and Bert O. Eijnde and Stephan P. Swinnen and Luc Vanhees and Marc van Leemputte and Peter Hespel and Ren{\'e} J. Dom},
  pages={925 - 930}
Objective: To evaluate the effect of creatine (Cr) supplementation (5 g/day) in Huntington’s disease (HD). Methods: A 1-year double-blind placebo-controlled study was performed in 41 patients with HD (stage I through III). At baseline and after 6 and 12 months, the functional, neuromuscular, and cognitive status of the patients was assessed by a test battery that consisted of 1) the Unified Huntington’s Disease Rating Scale (UHDRS), 2) an exercise test on an isokinetic dynamometer to assess… 

Tables from this paper

The CREST-E study of creatine for Huntington disease

The data do not support the use of creatine treatment for delaying functional decline in early manifest HD, and Class II evidence that for patients with early symptomatic HD, creatine monohydrate is not beneficial for slowing functional decline.

Creatine supplementation lowers brain glutamate levels in Huntington’s disease

A therapeutic potential of Cr in HD is indicated since Glu-mediated excitotoxicity is presumably pivotal in HD pathogenesis, and longterm clinical trials are warranted.

Effect of creatine supplementation as a potential adjuvant therapy to exercise training in cardiac patients: a randomized controlled trial

Oral creatine supplementation in combination with exercise training does not exert any additional effect on the improvement in physical performance, health related quality of life, lipid profile in patients with coronary artery disease or chronic heart failure than exercise training alone.

High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study

High-dose creatine was well tolerated, and total motor score, functional capacity, and neuropsychology testing remained stable at 12 months, and Serial 31P-MRS of muscle monitored changes in energy metabolism in vivo, and 1H-M RS was used to determine creatine levels in brain tissue.

Rating Scales and Performance‐based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations

The appraisal of the use and clinimetric properties of clinical measures of functional ability that have been applied in Huntington's disease studies and trials to date to make recommendations regarding their use based on standardized criteria found no rating scale targeting functional ability reached a “recommended” status.

An exploratory study of mobility-related outcome measures and an exercise intervention in people with Huntington's Disease (HD)

This study was the first systematic trial to demonstrate that a short-term structured exercise programme is acceptable and can be safely delivered in a home environment; achieve good adherence; and positively affect body function and activity in people with HD.

Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial.

Three months of creatine administration failed to detect any efficacy in treating symptoms of schizophrenia, but further research is suggested.

Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial.

Oral creatine supplements combined with home exercises improve functional performance without significant adverse effects in patients with polymyositis or dermatomyositis and appear safe, effective, and inexpensive.



Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial.

This is the first controlled study indicating that creatine supplementation improves skeletal muscle function in McArdle disease.

Rate of functional decline in Huntington’s disease

The comparable rates of decline on the TFC and the IS scores with other published studies suggest that these estimates of functional decline are representative of HD patients who are evaluated at HSG research sites, and should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.

Caffeine counteracts the ergogenic action of muscle creatine loading.

The data show that Cr supplementation elevates muscle PCr concentration and markedly improves performance during intense intermittent exercise, however, this ergogenic effect is completely eliminated by caffeine intake.

Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans

It is concluded that oral creatine supplementation stimulates muscle hypertrophy during rehabilitative strength training, mediated by a creatine‐induced change in MRF4 and myogenin expression.

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

This double‐blind, placebo‐controlled, sequential clinical trial did not find evidence of a beneficial effect of creatine monohydrate on survival or disease progression in patients with ALS.

Long-term creatine intake is beneficial to muscle performance during resistance training.

It is concluded that long-term creatine supplementation enhances the progress of muscle strength during resistance training in sedentary females.

Unified Huntington's disease rating scale: reliability and consistency

The limited longitudinal database indicates that the UHDRS may be useful for tracking changes in the clinical features of HD over time and there was an excellent degree of interrater reliability for the motor scores.

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations, supporting a role of metabolic dysfunction in a transgenic mouse model of HD and suggesting a novel therapeutic strategy to slow the pathological process.

Longitudinal evaluation of cognitive disorder in Huntington's disease

The study investigated longitudinal change in cognitive function in patients with Huntington's disease using a range of neuropsychological tests, which tap mental manipulative abilities, memory, and frontal executive skills, finding tasks sensitive to the progression of HD and hence most suitable for the evaluation of therapies.